Competition for targets, a tougher stance from regulators and uneven performance are likely to create an uneasy environment for healthcare special purpose acquisition companies in 2022, S&P Global reports. A total of 107 SPACs that listed parts of the healthcare industry as their intended target went public in 2021, according to S&P Global Market Intelligence data. Deal volume picked up in the last four months of the year, with 23 IPOs in November and December. That uptick in volume means more competition for healthcare companies that are mature enough to go public. Read more.
Related Posts
Byju’s Founder in $800M Funding Round with BlackRock Amid 3 SPAC Negotiations
The funding round has closed even as the Bangalore-headquartered edtech startup is in negotiations with at least three SPACs with plans to go public via a merger.
SPAC Investors Face Six Key Risks: Report
SPAC investors face several main risks, writes a REuters guest columnist. These include material misstatements, inadequate management due diligence, and inaccurate reporting.
So, SPACs are Dead Meat? Not a Chance, Asset Managers Say
The slowing SPAC craze is a good thing because it allows investors to better evaluate them, culling out the best, according to a panel of asset managers.
Opinion: The SPACsplosion has Reached a Reckoning
The proposed merger between blank-check company Churchill Capital IV and Lucid Motors is a pretty typical example of the pandemic SPACsplosion — it involves electric cars that have not yet been built, eye-popping forecasts and frothy trading, MarketWatch reports in this op/ed that takles a broader look at blank-check companies.